A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies

A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies

Trial Details

NCT ID
NCT04532203
Phase
EARLY_PHASE1
Sponsor
Zhejiang University
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • CAR-T cells
  • Ommaya Reservoir
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Inclusion criteria only for B-ALL:
  • Male or female aged 3-70 years;
  • Histologically confirmed diagnosis of B-ALL per the US National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Acute Lymphobl…
  • Relapsed or refractory CD19+ B-ALL (meeting one of the followingconditions):

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →